|
US7645743B2
(en)
*
|
1999-12-22 |
2010-01-12 |
Altermune, Llc |
Chemically programmable immunity
|
|
CA2328356A1
(en)
*
|
1999-12-22 |
2001-06-22 |
Itty Atcravi |
Recreational vehicles
|
|
WO2001061351A1
(en)
*
|
2000-02-17 |
2001-08-23 |
Laboratory Of Molecular Biophotonics |
Method for quantitatively detecting antigen
|
|
US8658773B2
(en)
|
2011-05-02 |
2014-02-25 |
Immunomedics, Inc. |
Ultrafiltration concentration of allotype selected antibodies for small-volume administration
|
|
EP1517700B1
(en)
*
|
2002-04-22 |
2012-03-28 |
Recopharma AB |
Mucin fusion polypeptide vaccines, compositions and methods of use thereof
|
|
US8193318B2
(en)
*
|
2002-08-14 |
2012-06-05 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
US8044180B2
(en)
*
|
2002-08-14 |
2011-10-25 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
US8530627B2
(en)
*
|
2002-08-14 |
2013-09-10 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
US8968730B2
(en)
*
|
2002-08-14 |
2015-03-03 |
Macrogenics Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
US8187593B2
(en)
*
|
2002-08-14 |
2012-05-29 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
DK1534335T4
(en)
|
2002-08-14 |
2015-10-05 |
Macrogenics Inc |
FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF
|
|
US8946387B2
(en)
*
|
2002-08-14 |
2015-02-03 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
DE10237317B4
(de)
*
|
2002-08-15 |
2010-04-08 |
3M Espe Ag |
Enzymhaltige Zusammensetzung, Verfahren zu deren Herstellung und deren Verwendung
|
|
CA2512729C
(en)
|
2003-01-09 |
2014-09-16 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant fc regions and methods of using same
|
|
US7960512B2
(en)
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
CA2512974A1
(en)
|
2003-01-13 |
2004-07-29 |
Macrogenics, Inc. |
Soluble fc.gamma.r fusion proteins and methods of use thereof
|
|
EP2230249A3
(en)
|
2003-02-06 |
2010-12-22 |
ChronTech Pharma AB |
Antigen/antibody or ligand/receptor glycosylated specificity exchangers
|
|
US20050059870A1
(en)
*
|
2003-08-25 |
2005-03-17 |
Aceti John Gregory |
Processing methods and apparatus for monitoring physiological parameters using physiological characteristics present within an auditory canal
|
|
US7544487B2
(en)
*
|
2004-02-13 |
2009-06-09 |
Immunomedics, Inc. |
Fusion proteins containing recombinant cytotoxic RNAses
|
|
JP5367982B2
(ja)
*
|
2004-04-16 |
2013-12-11 |
マクロジェニクス，インコーポレーテッド |
ＦｃγＲＩＩＢ特異的抗体とその利用法
|
|
CA2565874C
(en)
*
|
2004-05-10 |
2017-10-03 |
Macrogenics, Inc. |
Humanized fc.gamma.riib-specific antibodies and methods of use thereof
|
|
EP1600141B1
(en)
*
|
2004-05-24 |
2013-04-17 |
3M Deutschland GmbH |
Collagenolytic active enzyme containing compositions for the treatment of dental caries
|
|
DK1773884T3
(da)
|
2004-08-03 |
2012-05-21 |
Innate Pharma |
Terapeutiske og diagnostiske fremgangsmåder og sammensætninger til targeting af 4ig-b7-h3 og dets tilsvarende nk-celle-receptor
|
|
AU2005335714B2
(en)
|
2004-11-10 |
2012-07-26 |
Macrogenics, Inc. |
Engineering Fc antibody regions to confer effector function
|
|
ES2665422T3
(es)
|
2005-03-03 |
2018-04-25 |
Immunomedics Inc. |
Anticuerpos L243 humanizados
|
|
ES2971647T3
(es)
|
2005-04-15 |
2024-06-06 |
Macrogenics Inc |
Diacuerpos covalentes y usos de los mismos
|
|
FR2886298A1
(fr)
*
|
2005-05-24 |
2006-12-01 |
Ifremer |
Anticorps ou fragment d'anticorps couple a un agent immunogene
|
|
PL2573114T3
(pl)
|
2005-08-10 |
2016-10-31 |
|
Identyfikacja i inżynieria przeciwciał z wariantami regionów FC oraz sposoby ich stosowania
|
|
EP1754464A1
(en)
*
|
2005-08-17 |
2007-02-21 |
3M Innovative Properties Company |
Enzyme comprising dental composition
|
|
EP2674440B1
(en)
|
2005-12-16 |
2019-07-03 |
IBC Pharmaceuticals, Inc. |
Multivalent immunoglobulin-based bioactive assemblies
|
|
EP1999470A4
(en)
*
|
2006-03-10 |
2009-08-19 |
Macrogenics Inc |
IDENTIFICATION AND GENETIC MODIFICATION OF ANTIBODIES WITH HEAVY CHAINS OF VARIANTS AND METHODS OF USE THEREOF
|
|
WO2008105886A2
(en)
|
2006-05-26 |
2008-09-04 |
Macrogenics, Inc. |
HUMANIZED FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
|
|
ES2599319T3
(es)
|
2006-06-26 |
2017-02-01 |
Macrogenics, Inc. |
Anticuerpos específicos de Fc RIIB y métodos de uso de éstos
|
|
WO2008002933A2
(en)
*
|
2006-06-26 |
2008-01-03 |
Macrogenics, Inc. |
Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
|
|
US20080112961A1
(en)
*
|
2006-10-09 |
2008-05-15 |
Macrogenics, Inc. |
Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
|
|
US8652466B2
(en)
*
|
2006-12-08 |
2014-02-18 |
Macrogenics, Inc. |
Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
|
|
AU2014201846B2
(en)
*
|
2007-01-30 |
2016-07-07 |
Epivax, Inc. |
Regulatory t cell epitopes, compositions and uses thereof
|
|
AU2016203577B2
(en)
*
|
2007-01-30 |
2017-12-21 |
Epivax, Inc. |
Regulatory T cell epitopes, compositions and uses thereof
|
|
EP2450368A1
(en)
|
2007-01-30 |
2012-05-09 |
Epivax, Inc. |
Regulatory t cell epitopes, compositions and uses thereof
|
|
EP2158221B1
(en)
|
2007-06-21 |
2018-08-29 |
MacroGenics, Inc. |
Covalent diabodies and uses thereof
|
|
ES2589912T3
(es)
|
2008-04-02 |
2016-11-17 |
Macrogenics, Inc. |
Anticuerpos específicos para el complejo BCR y procedimientos de uso de los mismos
|
|
WO2009123894A2
(en)
|
2008-04-02 |
2009-10-08 |
Macrogenics, Inc. |
Her2/neu-specific antibodies and methods of using same
|
|
US20110081347A1
(en)
*
|
2008-06-04 |
2011-04-07 |
Macrogenics, Inc. |
Antibodies with Altered Binding to FcRn and Methods of Using Same
|
|
DK2786762T3
(da)
|
2008-12-19 |
2019-05-06 |
Macrogenics Inc |
Kovalente diabodies og anvendelser deraf
|
|
US20160095939A1
(en)
|
2014-10-07 |
2016-04-07 |
Immunomedics, Inc. |
Neoadjuvant use of antibody-drug conjugates
|
|
JP5757483B2
(ja)
*
|
2009-04-30 |
2015-07-29 |
国立大学法人広島大学 |
抗体性拒絶反応抑制剤
|
|
CN102459298A
(zh)
*
|
2009-05-05 |
2012-05-16 |
阿尔特姆恩科技责任有限公司 |
化学可编程免疫
|
|
EP2478110B1
(en)
|
2009-09-16 |
2016-01-06 |
Immunomedics, Inc. |
Class i anti-cea antibodies and uses thereof
|
|
JP5898082B2
(ja)
|
2009-10-07 |
2016-04-06 |
マクロジェニクス，インコーポレーテッド |
フコシル化程度の変更により改良されたエフェクター機能を示すＦｃ領域含有ポリペプチドおよびその使用法
|
|
ES2978177T3
(es)
|
2009-12-02 |
2024-09-06 |
Immunomedics Inc |
Combinación de radio inmunoterapia y conjugados anticuerpo-fármaco para mejorar la terapia contra el cáncer
|
|
EP2542256B1
(en)
|
2010-03-04 |
2019-05-22 |
MacroGenics, Inc. |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
|
PH12012501751A1
(en)
|
2010-03-04 |
2012-11-12 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
|
EP3323830B1
(en)
|
2010-06-19 |
2023-08-23 |
Memorial Sloan-Kettering Cancer Center |
Anti-gd2 antibodies
|
|
AU2011286024B2
(en)
|
2010-08-02 |
2014-08-07 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
|
US20120258496A1
(en)
*
|
2010-09-27 |
2012-10-11 |
Boehringer Ingelheim International Gmbh |
Production of low fucose antibodies in h4-ii-e rat cells
|
|
BR112013029892A2
(pt)
|
2011-05-21 |
2016-12-20 |
Macrogenics Inc |
polipeptídeo, molécula de ligação a antígeno, diacorpo e uso de uma porção polipeptídica de uma proteína de ligação a soro desimunizada
|
|
KR101566539B1
(ko)
|
2012-06-08 |
2015-11-05 |
국립암센터 |
신규한 Ｔｈ2 세포 전환용 에피토프 및 이의 용도
|
|
WO2017004144A1
(en)
|
2015-07-01 |
2017-01-05 |
Immunomedics, Inc. |
Antibody-sn-38 immunoconjugates with a cl2a linker
|
|
US9487587B2
(en)
|
2013-03-05 |
2016-11-08 |
Macrogenics, Inc. |
Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
|
|
SMT202100464T1
(it)
|
2013-03-14 |
2021-11-12 |
Macrogenics Inc |
Molecole bispecifiche che sono immunoreattive con cellule effettrici immunitarie che esprimono un recettore di attivazione
|
|
RU2680267C2
(ru)
|
2013-03-15 |
2019-02-19 |
Мемориал Слоан Кеттеринг Кэнсер Сентер |
Высокоаффинные антитела к gd2
|
|
KR20160135190A
(ko)
|
2014-02-14 |
2016-11-25 |
앤드류 에스. 카이 |
혈관형성 암의 치료를 위한 개선된 방법
|
|
CA2935748A1
(en)
|
2014-02-25 |
2015-09-03 |
Immunomedics, Inc. |
Humanized rfb4 anti-cd22 antibody
|
|
EA035419B9
(ru)
|
2014-05-29 |
2020-08-07 |
Мэкроудженикс, Инк. |
Триспецифичные связывающие молекулы и способы их применения
|
|
WO2018140026A1
(en)
|
2017-01-27 |
2018-08-02 |
Memorial Sloan Kettering Cancer Center |
Bispecific her2 and cd3 binding molecules
|
|
MX386297B
(es)
|
2014-09-29 |
2025-03-18 |
Univ Duke |
Moleculas biespecificas que comprenden un brazo orientado a la envoltura vih-1.
|
|
RU2017129236A
(ru)
|
2015-01-26 |
2019-03-07 |
Макродженикс, Инк. |
Мультивалентные молекулы, содержащие dr5-связывающие домены
|
|
CN107847584B
(zh)
|
2015-02-09 |
2022-01-25 |
纪念斯隆凯特琳癌症中心 |
具有人a33抗原和dota金属复合物亲和力的多特异性抗体及其用途
|
|
AU2016252771B2
(en)
|
2015-04-22 |
2021-12-16 |
Immunomedics, Inc. |
Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
|
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
|
AU2016274767B2
(en)
|
2015-06-09 |
2022-05-19 |
Eureka Therapeutics, Inc. |
T cell receptor-like antibody agents specific for EBV latent membrane protein 2A peptide presented by human HLA
|
|
TWI870335B
(zh)
|
2015-06-12 |
2025-01-21 |
美商宏觀基因股份有限公司 |
變異的嵌合4d5抗體及其與抗pd-1抗體聯合用於治療癌症的應用
|
|
HUE068868T2
(hu)
|
2015-07-30 |
2025-02-28 |
Macrogenics Inc |
PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások
|
|
IL260021B
(en)
|
2015-12-14 |
2022-09-01 |
Macrogenics Inc |
Bispecific molecules that are immunoreactive for pd1 and ctla4 and methods for using them
|
|
GEP20227398B
(en)
|
2016-04-15 |
2022-07-25 |
Macrogenics Inc |
Novel b7-h3 binding molecules, antibody drug conjugates thereof and usage thereof
|
|
CN112210010B
(zh)
|
2017-01-06 |
2023-12-05 |
优特力克斯有限公司 |
抗-人4-1bb抗体及其应用
|
|
EP3882271A3
(en)
|
2017-02-10 |
2022-01-05 |
Eutilex Co., Ltd. |
Ifn-gamma-inducible regulatory t cell convertible anti-cancer (irtca) antibody and uses thereof
|
|
GB201705686D0
(en)
*
|
2017-04-07 |
2017-05-24 |
Centauri Therapeutics Ltd |
Novel compounds and therapeutic uses thereof
|
|
CN112088169A
(zh)
|
2018-03-12 |
2020-12-15 |
纪念斯隆凯特琳癌症中心 |
双特异性结合剂及其用途
|
|
CN119930831A
(zh)
|
2018-03-14 |
2025-05-06 |
纪念斯隆凯特琳癌症中心 |
抗聚唾液酸抗体及其用途
|
|
GB201816553D0
(en)
|
2018-10-10 |
2018-11-28 |
Centauri Therapeutics Ltd |
Novel compounds and therapeutic uses thereof
|
|
EP3938400B1
(en)
|
2019-03-11 |
2025-07-30 |
Memorial Sloan Kettering Cancer Center |
Cd22 antibodies and methods of using the same
|
|
CA3204628A1
(en)
|
2021-01-13 |
2022-07-21 |
John T. POIRIER |
Antibody-pyrrolobenzodiazepine derivative conjugate
|
|
MX2023008285A
(es)
|
2021-01-13 |
2023-09-12 |
Memorial Sloan Kettering Cancer Center |
Conjugado de anticuerpo anti-dll3-farmaco.
|